0001171843-17-007020.txt : 20171114
0001171843-17-007020.hdr.sgml : 20171114
20171114170215
ACCESSION NUMBER: 0001171843-17-007020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171110
FILED AS OF DATE: 20171114
DATE AS OF CHANGE: 20171114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOHLIN GAREN G
CENTRAL INDEX KEY: 0001254705
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 171202658
MAIL ADDRESS:
STREET 1: C/O PRAECIS PHARMACEUTICALS INC
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTEON THERAPEUTICS INC
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 WEST STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-890-0102
MAIL ADDRESS:
STREET 1: 200 WEST STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
formfour.xml
OWNERSHIP DOCUMENT
X0306
4
2017-11-10
0
0001359931
PROTEON THERAPEUTICS INC
PRTO
0001254705
BOHLIN GAREN G
C/O PROTEON THERAPEUTICS, INC.
200 WEST STREET
WALTHAM
MA
02451
1
0
0
0
Common Stock
2017-11-10
4
A
0
23800
1.963
A
23800
D
Common Stock
2017-11-13
4
A
0
25700
1.918
A
49500
D
Common Stock
2017-11-14
4
A
0
3812
1.889
A
53312
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017.
The purchase price of $1.963 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.91 to $2.01. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The purchase price of $1.918 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.905 to $1.96. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The purchase price of $1.889 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.71 to $1.911. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ George A. Eldridge as attorney-in-fact for Garen Bohlin
2017-11-14